

Antiplasmodial activity of Ethanolic extract of Cassia spectabilis DC leaf and its inhibition effect in Heme detoxification

by Wiwied Ekasari

Submission date: 11-May-2021 02:00PM (UTC+0800)

Submission ID: 1583384717

File name: BMC Complement Med Ther_naskah.pdf (775.18K)

Word count: 7207

Character count: 35537

RESEARCH ARTICLE

Open Access

Antiplasmodial activity of Ethanolic extract of *Cassia spectabilis* DC leaf and its inhibition effect in Heme detoxification



Wiwied Ekasari^{1*}, Dewi Resty Basuki¹, Heny Arwati² and Tutik Sri Wahyuni¹

Abstract

Background: In previous studies, *Cassia spectabilis* DC leaf has shown a good antiplasmodial activity. Therefore, this study is a follow-up study of the extract of leaf of *C. spectabilis* DC on its *in vitro* and *in vivo* antiplasmodial activity and mechanism as an antimalarial.

Methods: The extract was fractionated, sub-fractionated and isolated to obtain the purified compound. *In vitro* antiplasmodial activity test against *Plasmodium falciparum* to find out the active compound. *In vivo* test against *P. berghei* ANKA-infected mice was conducted to determine prophylactic activity and antiplasmodial activity either alone or in combination with artesunate. The inhibition of heme detoxification test as one of the antimalarial mechanisms was carried out using the Basilico method.

Results: The results showed that active antimalarial compound isolated from *C. spectabilis* DC leaf had a structural pattern that was identical to (–)-7-hydroxycassine. Prophylactic test of 90% ethanolic extract of *C. spectabilis* DC leaf alone against *P. berghei* ANKA-infected mice obtained the highest percentage inhibition was 68.61%, while positive control (doxycycline 13 mg/kg) was 73.54%. In combination with artesunate, 150 mg/kg three times a day of *C. spectabilis* DC (D_0+D_2) + artesunate (D_2) was better than the standard combination of amodiaquine + artesunate where the inhibition percentages were 99.18 and 92.88%, respectively. The IC₅₀ of the extract for the inhibitory activity of heme detoxification was 0.375 mg/ml which was better than chloroquine diphosphate (0.682 mg/ml).

Conclusion: *C. spectabilis* DC leaf possessed potent antiplasmodial activity and may offer a potential agent for effective and affordable antimalarial phytomedicine.

Keywords: *Cassia spectabilis* DC, Combination, Heme detoxification, *Plasmodium berghei*, *Plasmodium falciparum*

* Correspondence: wiwied-e@ff.unair.ac.id; wiwiedeka@hotmail.com

¹Department of Pharmacognosy and Phytochemistry, Faculty of Pharmacy, Universitas Airlangga, Campus C, Mulyorejo Street, Surabaya 60115, Indonesia
Full list of author information is available at the end of the article



© The Author(s). 2021 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Background

Research to obtain new antimalarial drugs, both synthetic drugs and those derived from natural materials, especially from plants, is still ongoing. One of Indonesian plants that has been traditionally recognized to treat malaria is *Cassia spectabilis* DC from the Caesalpiniaceae family. Previous study related to this plant using in vivo test showed that this plant was a potential antimalarial phytomedicine [1]. New antimalarial active compounds have also been obtained from different plant, *Cassia siamea* from the same genus of *C. spectabilis* that identified as Cassiarin A alkaloid compound [2, 3]. Based on these results, an in vitro test on antiplasmodial activity to find out the active compound isolated from *C. spectabilis* DC has been conducted.

Prevention of malaria can be done in various ways, one of which is chemoprophylaxis. Chemoprophylaxis is one way to reduce the risk of malaria infection and alleviate clinical symptoms of malaria. Chemoprophylaxis used before traveling to malaria endemic area to avoid infection. In Indonesia, therapeutic choice used for malaria prophylaxis is doxycycline and tetracycline [4]. Both can be used as chemoprophylaxis for malaria but there are many undesirable effects from this drug [5]. Therefore, this research was performed to find out and develop drugs that can be used as an effective antimalarial prophylaxis, safe, have few side effects, cheap, and easy to obtain, especially those from plants, namely *C. spectabilis* DC leaf.

Furthermore, antimalarial drug development and discovery is expected to provide new drugs which is not only have antiplasmodial activity in vitro and in vivo, but also has a safety mechanism to be applied to human. Research related to the biochemical process that unique of malaria parasites plays an important role in the development of new antimalarial drugs. Malaria parasites consume hemoglobin from erythrocytes during their life cycle, however, parasites are unable to digest iron-containing heme molecule. Heme is toxic due to the reactivity of iron. Therefore, parasite has developed the mechanism to detoxify it by polymerization of heme to form hemozoin or malaria pigment [6, 7]. The structure of hemozoin through X-ray diffraction and IR spectroscopy has been found to be similar to β-hematin [8] β-hematin is synthetic hemozoin which chemically [8], spectroscopically [9] and crystallographically [10] similar to hemozoin which consists of Ferriprotoporphyrin units linked into a polymer by propionate oxygen-iron bonds [8, 11]. The inhibition of heme detoxification has been the target of antimalarial drugs, such as chloroquine and artemisinin [12, 13], since inhibit the heme detoxification can kill the parasites. Currently, the effect of ethanol extract of *C. spectabilis* DC leaf biochemical activity such as potential inhibition of heme detoxification in the food vacuole of malaria parasite and stage-

specific activity against asexual stage of parasite has been tested.

In addition, parasitic resistance to some of the existing antimalarial drugs is the biggest problem in overcoming this disease, especially in malaria endemic areas [14]. The combination therapy with artemisinin derivatives or commonly referred to artemisinin-based combination therapy (ACT) is highly recommended by WHO as the preferred therapy that is able to control the spread of resistance of *P. falciparum* [15, 16]. Previous studies have found an effective dose of 90% ethanolic extract of *C. spectabilis* DC leaf was 150 mg/kg bodyweight which were given three times daily [1].

Based on this result, both ethanolic extract of *C. spectabilis* DC leaf alone and in combination with artesunate has been tested to determine the inhibition of growth of parasites in *P. berghei* ANKA-infected mice in vivo, since the ACT is more effective in reducing parasitemia [17]. The combination therapy will be carried out in extract-drug regimens and an overview of the resulting antimalarial activity will be obtained. A therapeutic effect of an appropriate combination of artesunate and 90% ethanolic extract of *C. spectabilis* DC leaf is reported herein.

Methods

Plant material

C. spectabilis DC leaf was obtained from Purwodadi Botanical Garden-Indonesian Institute of Sciences [Lembaga Ilmu Pengetahuan Indonesia, LIPI], Pasuruan District, East Java Province, Indonesia, and the determination of specimen was performed at the above institution. The specimen was then deposited as herbarium in the Department of Pharmacognosy and Phytochemistry, Faculty of Pharmacy, Universitas Airlangga with registration number of 02/W/XI/2016.

Parasite and culture preparation

Plasmodium falciparum 3D7 strain was obtained from Faculty of Pharmacy, Universitas Airlangga, Surabaya. The parasite was cultured in complete RPMI 1640 medium supplemented with 5.96 g HEPES, 0.05 g hypoxanthine, 2.1 g NaHCO₃, 50 µg/ml gentamycin and completed with 10% human O+ serum under anaerobic condition and incubated in a 37 °C incubator [18]. Parasitemia was observed daily prior to antimalarial assay. *Plasmodium berghei* ANKA strain was originally obtained from Eijkman Institute for Molecular Biology, Jakarta, and maintained at Faculty of Pharmacy, Universitas Airlangga. The *P. berghei* ANKA was infected into male BALB/c mice and observed the parasitemia level.

Experimental animals

Experimental animal used in this study was BALB/c strain male mice obtained from Faculty of Veterinary

Medicine of Universitas Airlangga with a weight of $\pm 20\text{--}30\text{ g}$. Mice were acclimatized for 2 weeks at a temperature of $24 \pm 1^\circ\text{C}$ and humidity of $55 \pm 5\%$ prior to in vivo test. In all in vivo experiments, the animals were kept in cages with raised, wide-mesh floors to prevent coprophagy. The ethical certificate was obtained from the Ethic Commission of Faculty of Veterinary Medicine of Universitas Airlangga No: 2.KE.181.10.2018. At the end of the tests, all animals were followed the

euthanasia procedure. The mice were sacrificed by cervical dislocation after anesthesia by intraperitoneal injection of 100 mg/kg bodyweight ketamine [19]. The dead animals were then buried.

Extraction

The extract was made by three times macerating dried *C. spectabilis* DC leaf powder using 90% ethanol. The




Fig. 1 Flowchart of isolation steps of antiplasmodial alkaloid from *C. spectabilis* DC leaf

macerated extract was then evaporated using a rotavapor.

Isolation of compound from *C. spectabilis* DC leaf

A thousand grams of dried powder of *C. spectabilis* DC leaf was macerated with n-hexane, then the pulp powder was extracted again with methanol. The extract was subjected to liquid-liquid partition using ethyl acetate and 3% tartaric acid. The isolation process was done by adding 3% tartaric acid until the atmosphere becomes acidic to turn the alkaloids in alkaline form into alkaloids salts. This alkaloid salt was partitioned using ethyl acetate, and the alkaloids were present in the aqueous acidic layer at the bottom. The alkaloid was isolated from their salt form in aqueous layer, by adding NaCO₃ to increase the pH to 9–10, and the alkaloids returned to alkaline form. Furthermore, the aqueous layer with pH 9–10 was then extracted liquid-liquid using chloroform. The fractions so called chloroform fraction.

The isolate pure alkaloid compound from other compounds, the chloroform fraction, was further fractionation by column chromatography using stationary phase of silica gel 60 with a series of gradient mobile phases was started using 100% chloroform, chloroform: ethyl acetate (CHCl₃: EtOAc; 2:1), chloroform:methyl acetate:methanol (CHCl₃: EtOAc: MeOH; 2:1:2), and finally 100% methanol. The selection of the mobile phase was based on the results of the orientation by TLC, which gave good separation results. The solvent used for each gradient was 200 ml and the collected fractions were combined based on similarity of the TLC profile. Nine fractions (C.1-C.9) were obtained.

The fractions were then assayed for their antiplasmoidal activity. The active fraction was then subjected to silica gel 60 column chromatography and was eluted using CHCl₃: MeOH (1: 00: 1) to yield sub-fractions (SFC.8.1-SFC.8.4). The sub-fractions were further assayed for their antiplasmoidal activity. The antimarial active sub-fraction was then purified by preparative thin-layer chromatography (PTLC) using CHCl₃: MeOH (8.5: 1.5) to yield compounds C.8.3.1 and C.8.3.2. Identification of active compound was carried out using the TLC-densitometry, UV-Vis spectrophotometry, FTIR spectroscopy, and NMR. The procedures employed for the

preparation of the plant active compounds are illustrated in Fig. 1.

In vitro antiplasmoidal activity test

The extract was dissolved in DMSO (the final DMSO concentration in a well culture plate not more than 0.5%) and diluted with complete RPMI medium containing RPMI 1640, 10% human plasma, 25 mM HEPES, and 25 mM NaHCO₃ to make the final concentration of 10, 1, 0.1, 0.01, and 0.001 µg/ml. Stock of parasite cultures were further diluted with uninfected type O+ human erythrocytes and culture medium to make initial parasitemia of 1% and a hematocrit of 2%. This final parasite culture was immediately used for antiplasmoidal assay. The test was carried out in duplicate. The plates containing parasite cultures and extracts were then incubated in a 37 °C incubator in a candle jar for 48 h. Observation of stage-specific antiplasmoidal activity in this in vitro test was performed by sampling the blood films from each well at 6, 12, 24, and 48 h. At the end of test thin films were prepared from each well and stained with 10% Giemsa solution prior to counting parasitemia [20]. The 50% inhibitory concentration (IC₅₀) value was determined using probit analysis based on the relation of log concentration of test compound and % inhibition of parasites growth.

25

In vivo antimarial prophylactic activity test

In vivo test for antimarial prophylactic activity of 90% ethanolic extract of *C. spectabilis* DC leaf used P₁₄ method with slight modification [21]. Forty two male adult BALB/c mice were randomly divided into six groups [22]. Group 1 as a negative control group was given a 0.5% NaCM suspension solution. Groups 2, 3, 4, and 5 were given extract at the doses of 100, 200, 400, and 800 mg/kg respectively. Group 6 as a positive control group was given a doxycycline of 13 mg/kg suspension solution. Each treatment was given orally once a day for 4 days before parasite infection. On the fourth day the mice were infected with *P. berghei* ANKA. Each mouse in each group was infected with 1 × 10⁶ infected erythrocytes. Thin blood films from each mouse were made at 72 h post infection. Determination of parasitemia, percentage of the parasites' growth, percentage

Table 1 The percentage growth inhibition of *P. falciparum* 3D7 by extract and fractions of *C. spectabilis* DC leaf

Extract/fraction	Weight (g)	Concentration (µg/ml)					IC ₅₀ (µg/ml)
		100	10	1	0.1	0.01	
Hexane extract	118.34	0	0	0	0	0	ND
Methanolic extract	141.68	100	68.67 ± 5.19	14.36 ± 2.26	0	0	1.10
Ethyl acetate fraction	100.21	100	96.56 ± 4.86	75.47 ± 3.38	16.41 ± 3.78	0	0.41
Chloroform fraction	4.06	100	79.80 ± 1.87	56.36 ± 12.12	31.38 ± 12.58	0	0.55

ND Not Detected

Table 2 The percentage growth inhibition of *P. falciparum* 3D7 by chloroform fractions of *C. spectabilis* DC leaf

Weight of fraction (mg)	Concentration ($\mu\text{g/ml}$)					IC_{50} ($\mu\text{g/ml}$)
	10	1	0.1	0.01	0.001	
C.1	20.00	27.97 \pm 5.46	0	0	0	> 10
C.2	4.10	0	0	0	0	ND
C.3	13.90	31.82 \pm 3.51	6.39 \pm 3.95	0	0	> 10
C.4	17.90	93.07 \pm 6.36	59.02 \pm 1.38	28.22 \pm 8.39	10.54 \pm 9.24	0.384
C.5	7.70	100	62.74 \pm 6.03	24.03 \pm 1.19	0	1–0.1
C.6	104.40	97.40 \pm 3.67	93.50 \pm 6.81	65.50 \pm 18.95	14.92 \pm 7.44	0.060
C.7	94.20	91.90 \pm 1.23	84.84 \pm 2.91	68.22 \pm 4.91	48.83 \pm 11.03	0.011
C.8	366.10	100	100	84.39 \pm 7.54	66.26 \pm 3.58	42.90 \pm 4.50
C.9	36.50	100	87.36 \pm 6.41	65.51 \pm 3.78	58.52 \pm 1.33	0.005

ND Not Detected

inhibition of parasites' growth, and effective dose 50 (ED_{50}) were based on Ekasari et al. [20].

Suppressive effect of ethanolic extract of *C. spectabilis* DC leaf combined with artesunate

The purpose of this test was to increase the effectiveness of the extract. The suppressive effect of ethanolic extract of *C. spectabilis* DC leaf in combination with artesunate, respectively against *P. berghei* ANKA infection in mice was determined using Peters' 4-day suppression test procedure [21]. A donor mouse densely infected with parasites was anaesthetized with chloroform and the blood was collected through cardiac puncture. The presence of parasitemia was established by microscopic examination of a thin blood film. The blood was diluted with phosphate buffered saline (PBS) so that each 0.2 ml of blood contained 11×10^6 *P. berghei* ANKA infected with erythrocytes. A total of 0.2 ml of diluted blood was injected intraperitoneally into 36 healthy mice. The infected animals were randomly divided into six groups those were Group A-F. The animals were treated shortly after inoculation on day zero (D_0). Group A was given artesunate at 36.4 mg/kg, on D_0 - D_2 . Group B was given ethanolic extract of *C. spectabilis* DC leaf at 150 mg/kg (three times a day) concurrently with artesunate at 36.4 mg/kg (once a day), on D_0 - D_2 . Group C was given

ethanolic extract of *C. spectabilis* DC leaf at 150 mg/kg (three times a day) on D_0 - D_2 and artesunate at 36.4 mg/kg (once a day), on D_0 . Group D was given ethanolic extract of *C. spectabilis* DC leaf at 150 mg/kg (three times a day) on D_0 - D_2 and artesunate at 36.4 mg/kg (once a day), on D_2 . Group E was given amodiaquine at 72.8 mg/kg concurrently with artesunate at 36.4 mg/kg, once a day, on D_0 - D_2 . Group F received 0.2 ml of 0.5% Na CMC solution as control group. Oral route was used for administration. On day three (D_3), thin film was made from each mouse-tail blood stained with Giemsa. Determination of parasitemia level, percentage parasites' growth, percentage inhibition of parasites' growth, and the ED_{50} were as described on Ekasari et al. [20].

Heme polymerization inhibition test

The inhibition of heme polymerization test was performed based on the Basilico method [23] with slight modification in the concentration of hematin solution and the sample used. The Basilico method is an in vitro spectrophotometric microassay of heme polymerization. A 10 well U-bottomed microplates was used in this assay. The relative amounts of polymerized and unpolymerized hematin were determined using an ELISA reader. The final concentration of the extract samples ranged from 2 to 0.01 mg/ml.

Table 3 The percentage growth inhibition of *P. falciparum* 3D7 by sub-fractions of *C. spectabilis* DC leaf

Sub-fraction	Weight (mg)	Concentration ($\mu\text{g/ml}$)					IC_{50} ($\mu\text{g/ml}$)
		10	1	0.1	0.01	0.001	
SFC.8.1	8.65	99.56 \pm 0.59	86.42 \pm 3.19	70.95 \pm 0.17	62.71 \pm 3.82	53.30 \pm 4.67	0.001
SFC.8.2	11.25	0	0	0	0	0	0
SFC.8.3	32.50	100	72.84 \pm 6.81	62.58 \pm 6.01	46.59 \pm 0.47	31.08 \pm 7.40	0.016
SFC.8.4	20.50	76.74 \pm 16.36	0	0	0	0	> 1

Table 4 The percentage growth inhibition of *P. falciparum* 3D7 by compounds C.8.3.1 and C.8.3.2 of *C. spectabilis* DC leaf

Compound	Weight (mg)	Concentration ($\mu\text{g}/\text{ml}$)					IC_{50} ($\mu\text{g}/\text{ml}$)
		10	1	0.1	0.01	0.001	
C.8.3.1	4.30	97.23 \pm 1.49	80.11 \pm 0.69	67.61 \pm 1.93	46.77 \pm 0.91	27.71 \pm 1.35	0.016
C.8.3.2	2.60	100	77.21 \pm 2.81	50.56 \pm 10.48	31.96 \pm 13.61	0	0.070

⁴ A 100 μl of 1 mM hematin solution was mixed with 0.2 M NaOH and 50 μl of the test extract. A 50 μl of glacial acetic acid solution (H 2.6) was then added to this mixture. ²⁶'s test was carried out at 37 °C for 24 h. The microtube was then centrifuged at 8000 rpm for 10 min, the sediment was then washed with 200 μl of DMSO three times at 8000 rpm for 10 min. The β -hematin crystalline precipitated was dissolved in 200 μl of NaOH 0.1 M to form alkaline hematin. A 100 μl of the alkaline hematin solution was transferred to 96-well microplates and the absorbance was read by ELISA reader at a wavelength of 405 nm. The effects of each test substance on β -hematin production were calculated and compared with negative controls.

Results


In vitro antiplasmoidal activity test


All the extracts, fractions, sub-fractions, and isolated compounds from *C. spectabilis* DC leaf were continuously screened in vitro for their antiplasmoidal activity against chloroquine-sensitive *P. falciparum* (3D7 strain), using microtechnique which demonstrated on the previous study [24]. The samples for these tests were hexane extract, methanolic extract, ethyl acetate fraction and chloroform fraction. The results are shown in Table 1. Antiplasmoidal activity was classified based on the Gessler et al. [25], where antiplasmoidal activity ⁴¹ extract was considered very good, moderate, and low with IC_{50} value less than 10 $\mu\text{g}/\text{ml}$, 10 to 50 $\mu\text{g}/\text{ml}$, and more than 50 $\mu\text{g}/\text{ml}$, respectively.

During isolation of compound, chloroform was used to fractionate the extract. Chloroform fractionation resulted in nine fractions called C.1-C.9. In vitro antiplasmoidal activity test of these fractions showed that fraction C.8 was the most active fraction with IC_{50} was 0.02 $\mu\text{g}/\text{ml}$ (Table 2). Purification of fraction C.8 resulted in four sub-fractions called SFC.8.1-SFC.8.4, and their antiplasmoidal activity is shown in Table 3. Sub-fraction SFC.8.1 and SFC.8.3 showed antiplasmoidal activity against *P. falciparum* 3D7 strain with IC_{50} 0.012 and 0.015 $\mu\text{g}/\text{ml}$, respectively. The purification of sub-fractions SFC.8.3 resulted in two compounds called compound C.8.3.1 and C.8.3.2 and their antiplasmoidal activity is shown in Table 4 and Fig. 2. Compound C.8.3.1 and C.8.3.2 showed antiplasmoidal activity against *P. falciparum* 3D7 strain with IC_{50} 0.016 and 0.070 $\mu\text{g}/\text{ml}$, respectively.

Identification using TLC-densitometry showed that compound C.8.3.1 was in the range of λ 200–300 nm, with a value of $R_F = 0.65$. Identification using FTIR spectroscopy showed an absorption peak at 472.53 cm^{-1} ; 657.68 cm^{-1} ; 786.9 cm^{-1} ; 864.05 cm^{-1} ; 1101.28 cm^{-1} ; 1382.87 cm^{-1} (Fig. 3).

Identification using $^1\text{H-NMR}$ spectroscopy showed a characteristic signal of two hydroxyl protons at δ 3.60 ppm (1H, s); and δ 3.69 ppm (1H, s), two protons from the CH_2 group of benzene at δ 1.91 ppm (2H, s, H-4) and δ 1.68 ppm (2H, s, H-5), one methyl group at δ 2.13 ppm (3H, s, H-12'), and some ³⁰ carbonates of the CH_2 groups of the aliphatic chain at δ 1.38 ppm (2H, s, H-1'); at δ 1.22 ppm (2H, s, H-2'– H-8'); at δ 1.51 ppm (2H, s, H-9'), and at δ 2.35 ppm (2H, t, H-10'). Identification using $^{13}\text{C-NMR}$ spectroscopy showed the presence of one carbon with a ketone group at δ 179.0 ppm, carbon in the benzene group at δ 56.96 ppm; δ 67.13 ppm; δ 29.23 ppm; δ 25.77 ppm; and δ 48.29 ppm, carbon in the aliphatic chain at δ 34.32 ppm; δ 25.87 ppm; δ 29.23 ppm; δ 29.33 ppm; δ 22.89 ppm; and δ 38.87 ppm, one carbon in the methyl group at δ 30.23 ppm, and one carbon in the hydroxyl group at δ 65.27 ppm.





Effect of *C. spectabilis* on parasitic stage development

Stage-specific activity test of 90% ethanolic extract of *C. spectabilis* DC leaf against *P. falciparum* 3D7 strain was performed at different incubation periods of 0, 6, 12, 24, and 48 h to find out the effect of the extract to the growth of parasites at each stage of development. The

extract concentration used was 100 µg/ml. The results of this experiment are shown in Table 5 and Fig. 4.

No sharp difference was observed on the growth of each parasitic stage during incubation period of 0–12 h. However, opposite direction of percentage parasitemia was seen at 12 to 48 h post incubation compared with

Table 5 Stage-specific activity of 90% ethanolic extracts of *C. spectabilis* DC leaf against *P. falciparum* 3D7 strain

Samples	Incubation time (hours)	Parasitic stage			% parasitemia	% growth	% inhibition
		Ring	Trophozoite	Schizont			
Negative control	0	41	5	1	0.76	—	—
	6	38	11	2	0.84	0.08	—
	12	36	15	2	0.86	0.10	—
	24	45	19	7	1.14	0.38	—
	48	95	30	4	2.06	1.30	—
90% ethanolic extract of <i>C. spectabilis</i> DC leaf	0	41	5	1	0.76	—	—
	6	38	10	1	0.81	0.05	37.5
	12	34	11	5	0.79	0.03	70
	24	22	13	2	0.59	0	100
	48	17	0	0	0.28	0	100

% parasitemia was obtained from total number of parasites divide to ring, trophozoite and schizont

% growth was obtained from % parasitemia an incubation time minus % parasitemia at 0 h

% inhibition was calculated according to the following formula: % inhibition = ((parasitemia in negative control – parasitemia in treatment group) / parasitemia in negative control) × 100

Negative control: The cultures were only added with DMSO, without any extract. The DMSO was used as negative control because DMSO was used to dissolve the extract




Fig. 4 Stages development of *P. falciparum* 3D7 in vitro treated with 90% ethanolic extract of *C. spectabilis* DC leaf at different incubation time. Parasitic morphology and the development of each stage were assessed at the beginning of incubation (0 h) and at 6, 12, 24, and 48 h. The stages of parasite were classified in three groups: ring, trophozoite, and schizont. The parasitic differential count was reported as a percentage of the total red blood cells infected with those stages. Five bars in each group according to different incubation times (left to right): 0, 6, 12, 24, and 48 h. EECS = 90% ethanolic extract of *C. spectabilis* DC leaf. * $p < 0.05$

control which moved upward but the tests extract went to 0. At 12–24 h of incubation period, parasite growth decreased but not significantly compared to negative control. Whereas at 48 h of incubation, parasite growth decreased significantly ($p = 0.005$) compared to negative control, with an inhibition percentage of 100% (Fig. 5).




Fig. 5 Percentage of parasitemia of 90% ethanolic extract *C. spectabilis* DC leaf and control at each incubation time against *P. falciparum* 3D7 in vitro. EECS = 90% ethanolic extract of *C. spectabilis* DC leaf. * $p < 0.05$

In vivo antiplasmodial prophylactic activity test

The results of ² vivo antiplasmodial prophylactic activity test of 90% ethanolic extract of *C. spectabilis* DC leaf against *P. berghei* ANKA infection in mice is shown in Table 6.

The dose of extract of 800 mg/kg provided the greatest inhibitory effect (68.61%) compared to other doses. Probit analysis resulted in ED₅₀ value was 161.20 mg/kg.

In vivo antiplasmodial suppressive activity test

Table 7 shows the results of suppressive activity tests by ¹ *C. spectabilis* DC leaf extract combined with artesunate. Suppressive effects produced by the three extract-artesunate combinations were higher than artesunate alone. Moreover, the suppressive effects of group D (ethanolic extract of *C. spectabilis* DC leaf at 150 mg/kg (three times a day) on D₀-D₂ and artesunate at 36.4 mg/kg on D₂) was higher (99.18%) than those showed by artesunate alone (82.60%) and artesunate-amodiaquine combination (92.88%).

Heme polymerization inhibition test

The IC₅₀ value of the heme inhibition test by 90% ethanolic extract of *C. spectabilis* DC leaf was 0.375 mg/ml, while chloroquine as an antimalarial standard compound was 0.682 mg/ml (Table 8).

Discussion

Anti-malarial activities of *C. spectabilis* DC leaf was conducted to extract, fraction and pure isolate. The active

Table 6 Prophylactic effects of 90% ethanol extract of *C. spectabilis* DC leaf to the growth of parasites compared with controls

Sample	Dose (mg/kg)	Parasitemia (%)	Inhibition (%)
90% ethanolic extract of <i>C. spectabilis</i> DC leaf	100	5.95 ± 1.21	40.14
	200	4.06 ± 1.00	59.16
	400	3.97 ± 0.89	60.06
	800	3.12 ± 0.44	68.61
Doxycycline	13	2.63 ± 0.88	73.54
Na CMC	–	9.94 ± 1.81	–

Na CMC were used as a negative control

compounds were identified by TLC-densitometry, UV-Vis spectrophotometry, FTIR spectroscopy, and NMR. In the ¹H-NMR spectra, compound C.8.3.1 showed similarities to the compound (−)-7-hydroxycassine (Fig. 6) in the presence of several similar chemical shifts [26].

The greatest prophylactic inhibitory effect in vivo of 90% ethanolic extract of *C. spectabilis* DC leaf against *P. berghei* ANKA was 68.61% provided by the mice treated with 800 mg/kg of the extract. This result was lower than that of mice treated with doxycycline (73.54%). The highest dose that can be used in mice is 1000 mg/kg of bodyweight [27].

The effect of 90% ethanolic extract of *C. spectabilis* DC leaf to inhibit heme detoxification process showed the IC₅₀ value of 0.375 mg/ml which was higher than that of chloroquine as a standard antimalarial drug which was 0.682 mg/ml.

The potential for 90% ethanolic extract of *C. spectabilis* DC leaf in the inhibition of hemozoin formation caused morphological and growth disturbances of malaria parasites due to membrane damage and disruption of the activity of several enzymes [28] as seen during the 12-h incubation period where the inhibitory activity 70% increase compared to controls. Furthermore, after 24 h incubation, the growth of parasites was 100% inhibited compared to the control (Table 5).

The advantage of the combination therapy was to increase the effectiveness of extract to prevent or slow the onset of resistance to a single antimalarial drug [29]. Selection of 90% ethanolic extract of *C. spectabilis* DC leaf

combination with artesunate referred to the basis of malaria treatment which is a standard antimalarial drug recommended by WHO [30].

The dose of 90% ethanolic extract of *C. spectabilis* DC leaf used was 150 mg/kg given three times [1]. Artesunate is the artemisinin derivative is a schizonticidal with fast onset of action and gametocytocidal which can reduce malaria transmission in endemic areas [31]. Artesunate at a dose of 36.4 mg/kg was converted dose from human to mouse. The three times a day of artesunate therapy was compared to single dose therapy to prevent the immediate emerging of parasites resistance to this antimalarial drug. The control used in this study was a single dose of artesunate alone at the dose of 36.4 mg/kg and amodiaquine alone at the dose of 72.8 mg/kg which were given for 3 days. As recommended by WHO that ACT administration that given for 3 days has been able to effectively inhibit the growth of parasites, beside antimalarial drug should be effective, safe, and used in a short time. The Na CMC was used as negative control since this solvent was used to dissolve the extract in this test.

The interesting result was seen in the combination therapy using three times a day of 90% ethanol extract of *C. spectabilis* DC leaf at dose of 150 mg/kg for 3 days with a single dose of artesunate at the dose of 36.4 mg/kg given on the third day. This combination therapy showed a higher inhibitory activity (99.18%) compared to that of combination artesunate and amodiaquine for 3 days (92.88%). This combination therapy may overcome

Table 7 Suppressive effect of 90% ethanolic extract of *C. spectabilis* DC leaf combined with artesunate to the growth of parasite in mice

Treatment	Parasitemia count		Suppression (%)
	D ₀	D ₃	
Na CMC	1.84 ± 0.59	9.14 ± 2.38	–
<i>C. spectabilis</i> DC + Artesunate (D ₀ -D ₃)	2.01 ± 0.64	3.11 ± 1.30	84.93
<i>C. spectabilis</i> DC (D ₀ -D ₃) + Artesunate (D ₀)	2.92 ± 0.73	3.40 ± 1.21	90.14
<i>C. spectabilis</i> DC (D ₀ -D ₃) + Artesunate (D ₃)	2.22 ± 1.14	2.08 ± 1.28	99.18
Artesunate	2.27 ± 0.76	3.40 ± 1.24	82.60
Amodiaquine + Artesunate	1.62 ± 0.74	1.97 ± 0.68	92.88

Na CMC were used as a negative control

Table 8 Inhibitory effect of 90% ethanolic extract of *C. spectabilis* DC leaf on the heme polymerization compared with controls

Samples	Concentration (mg/ml)	Level of hematin (mM)	Inhibition (%)	IC_{50} (mg/ml)
90% ethanolic extract of <i>C. spectabilis</i> DC leaf	2	67.32 ± 4.49	76.49 ± 1.57	0.375
	1	85.34 ± 1.42	70.20 ± 0.50	
	0.5	118.49 ± 2.92	58.62 ± 1.02	
	0.25	186.37 ± 6.55	34.91 ± 2.29	
	0.1	223.85 ± 4.35	21.82 ± 1.52	
	0.01	252.00 ± 1.85	11.99 ± 0.64	
Chloroquine diphosphate	2	99.80 ± 2.50	65.15 ± 0.97	0.682
	1	125.65 ± 4.03	56.12 ± 1.41	
	0.5	158.00 ± 4.63	44.82 ± 1.62	
	0.25	186.78 ± 3.95	34.76 ± 1.38	
	0.1	207.05 ± 1.96	27.69 ± 0.68	
	0.01	229.53 ± 9.26	19.84 ± 3.24	
DMSO	–	286.33 ± 2.92	–	–

DMSO were used as a negative control

the resistance of parasites to artesunate because shorten the duration of treatment period. Thus, the combination of 90% ethanolic extract of *C. spectabilis* DC leaf with artesunate can be expected as a new antimalarial combination drug which may replace the artesunate-amodiaquine combination drug that has been used so far. The mixture of artesunate-amodiaquine caused the drug preparations will become unstable [32]. Concurrent drug administration in a separate formula have the disadvantage of reducing patient compliance to take the drug, but the combination therapy can shorten the duration of treatment therapy [30].

Conclusion

The results show 90% ethanolic extract of *C. spectabilis* DC leaf has a very good antiplasmodial activities both in vitro and in vivo study and revealed potentiated effect in combination with artesunate. The 90% ethanol extract of *C. spectabilis* DC leaf also found to be active in inhibiting the heme detoxification process. Compound of (–)-7-hydroxycassine may play as important role in antimalarial activities. Therefore, this plant can be potentially used as a new source for the development of new plant-based antimalarial agent.




Fig. 6 Molecular structure of (–)-7-hydroxycassine

Abbreviations

ACT: Artemisinin-based combination therapy; CHCl_3 : Chloroform; DMSO: Dimethyl sulfoxide; ED_{50} : Median effective dose; EECS: Ethanolic extract of *Cassia spectabilis* DC leaf; ELISA: Enzyme-linked immunosorbent assay; EtOAc: Ethyl acetate; Fe(II)PPX: Ferrous-protoporphyrin IX; FTIR: Fourier transform infrared; HEPEs: N-2-hydroxyethylpiperazine-N-ethanesulfonic acid; IC_{50} : The half maximal inhibitory concentration; IR: Infrared; MeOH: Methanol; NaCMC: Sodium carboxymethylcellulose; $NaHCO_3$: Sodium bicarbonate; NaOH: Sodium hydroxide; NMR: Nuclear magnetic resonance; Phosphate buffered saline; PTLC: Preparative thin-layer chromatography; RPMI: Roswell Park Memorial Institute; TLC: Thin-layer chromatography; UV-Vis: Ultraviolet-visible; WHO: World health organization

Acknowledgments

We would like to thank The Ministry of Research, Technology, and Higher Education of the Republic of Indonesia [Kementerian Riset, Teknologi, dan Pendidikan Tinggi Republik Indonesia, RISTEKDIKTI RI] scheme for financial support.

Authors' contributions

Conceived and designed the experiment: WE, DRB, HA and TSW. Analyzed the data: WE and HA. Contributed reagents/materials/analysis tools: WE. Wrote the manuscript: WE, DRB and TSW. All authors read and approved the final manuscript.

Funding

This research was granted by The Ministry of Research, Technology, and Higher Education of the Republic of Indonesia with grant number 586/UN3/2017. The funders had no role in the study design and analysis.

Availability of data and materials

The all data used to support the findings of this study are available from the corresponding authors upon request.

Ethics approval and consent to participate

This work was approved by Animal care and Use Committee, Airlangga University, No 2KE.181.10.2018.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing of interest.

Author details

¹Department of Pharmacognosy and Phytochemistry, Faculty of Pharmacy, Universitas Airlangga, Campus C, Mulyorejo Street, Surabaya 60115, Indonesia. ²Department of Medical Parasitology, Faculty of Medicine, Universitas Airlangga, Campus A, Surabaya 60132, Indonesia.

Received: 2 March 2020 Accepted: 2 February 2021

Published online: 19 February 2021

References

- Ekasari W, Wahyuni TS, Arwati H, Putri NT. Determination of effective dose antimalarial from *Cassia spectabilis* leaf ethanol extract in *Plasmodium berghei*-infected mice. Afr J Infect Dis. 2018;12(1 Suppl):110–5.
- Morita H, Oshima S, Hirasawa Y, Koyama K, Honda T, Ekasari W, et al. Cassiarins a and b, novel antiplasmodial alkaloids from *Cassia siamea*. Org Lett. 2007;9(18):3691–3.
- Ekasari W, Widyawaruyanti A, Zaini NC. Antimalarial activity of cassiarin a from the leaves of *Cassia siamea*. Heterocycles. 2009;78(7):1831–6.
- Elyazar IRF, Hay SI, Baird JK. Malaria distribution, prevalence, drug resistance and control in Indonesia. Adv Parasitol. 2011;74:41–175.
- Tan KR, Magill AJ, Parise ME, Arguin PM. Doxycycline for malaria chemoprophylaxis and treatment: report from the CDC expert meeting on malaria chemoprophylaxis. Am J Trop Med Hyg. 2011;84(4):517–31.
- Chugh M, Sundaraman V, Kumar S, Reddy VS, Siddiqui WA, Stuart KD, et al. Protein complex directs hemoglobin-to-hemozoin formation in *Plasmodium falciparum*. Proc Natl Acad Sci U S A. 2013;110(14):5392–7.
- Slater AF, Cerami A. Inhibition by chloroquine of a novel haem polymerase enzyme activity in malaria trophozoites. Nature. 1992;355(6356):167–9.
- Slater AF, Swiggard WJ, Orton BR, Flitter WD, Goldberg DE, Cerami A, et al. An iron-carboxylate bond links the heme units of malaria pigment. Proc Natl Acad Sci U S A. 1991;88(2):325–9.
- Bohle DS, Conklin BJ, Cox D, Madsen SK, Paulson S, Stephens PW, et al. Structural and spectroscopic studies of β -hematin (the heme coordination polymer in malaria pigment). Inorganic and organometallic polymers II. ACS Symposium Series. Am Chem Soc. 1994;572:497–515.
- Bohle S, Dinnebier R, Madsen S, Stephens P, Bohle SD, Dinnebier RE, Madsen SK, Stephens PW. Characterization of the products of the heme detoxification pathway in malarial late trophozoites by X-ray diffraction. J Biol Chem. 1997;272:713–6.
- Pagola S, Stephens PW, Bohle DS, Kosar AD, Madsen SK. The structure of malaria pigment beta-haematin. Nature. 2000;404(6775):307–10.
- Fong KY, Wright DW. Hemozoin and antimalarial drug discovery. Future Med Chem. 2013;5(12):1437–50.
- Olafson KN, Ketchum MA, Rimer JD, Vekilov PG. Mechanisms of hematin crystallization and inhibition by the antimalarial drug chloroquine. Proc Natl Acad Sci U S A. 2015;112(16):4946–51.
- Kremsner PG, Krishna S. Antimalarial combinations. Lancet. 2004;364(9430):285–94.
- Nandakumar DN, Nagaraj VA, Vathsala PG, Rangarajan P, Padmanaban G. Curcumin-artemisinin combination therapy for malaria. Antimicrob Agents Chemother. 2006;50(5):1859–60.
- WHO. Artemisinin resistance and artemisinin-based combination therapy efficacy: status report, vol. 2018. Geneva: World Health Organization; 2018. Contract No: WHO/CDS/GMP/2018.18.
- Alvarez G, Tobón A, Piñeros J-G, Ríos A, Blair S. Dynamics of *Plasmodium falciparum* parasitemia regarding combined treatment regimens for acute uncomplicated malaria, Antioquia, Colombia. Am J Trop Med Hyg. 2010; 83(1):90–6.
- Trager W, Jensen JB. Human malaria parasites in continuous culture. 1976. J Parasitol. 2005;91(3):484–6.
- Carbone L, Carbone ET, Yi EM, Bauer DB, Lindstrom KA, Parker JM, et al. Assessing cervical dislocation as a humane euthanasia method in mice. J Am Assoc Lab Anim Sci. 2012;51(3):352–6.
- Ekasari W, Widya Pratiwi D, Amanda Z, Suciaty WA, Arwati H. Various parts of *Helianthus annuus* plants as new sources of antimalarial drugs. Evid Based Complement Alternat Med. 2019;20197390385.
- Peters W. The chemotherapy of rodent malaria, XXII. The value of drug-resistant strains of *P. berghei* in screening for blood schizontocidal activity. Ann Trop Med Parasitol. 1975;69(2):155–71.
- Lemeshow S, Hosmer DW, Klar J, Lwanga SK, World HO. Adequacy of sample size in health studies / Stanley Lemeshow. Chichester: Wiley; 1990.
- Basilico N, Pagani E, Monti D, Olliari P, Taramelli D. A microtitre-based method for measuring the haem polymerization inhibitory activity (HPIA) of antimalarial drugs. J Antimicrob Chemother. 1998;42(1):55–60.
- Rieckmann KH, Campbell GH, Sax LJ, Mrema JE. Drug sensitivity of *Plasmodium falciparum*. An *in-vitro* microtechnique. Lancet. 1978;1(8054):22–3.
- Gessler MC, Nkunya MH, Mwasumbi LB, Heinrich M, Tanner M. Screening Tanzanian medicinal plants for antimalarial activity. Acta Trop. 1994;56(1): 65–77.
- Viegas Junior C, Pivatto M, Ad R, Hamerski L, DHS S, VdS B. (–)-7-hydroxycassine: a new 2,6-dialkylpiperidin-3-ol alkaloid and other constituents isolated from flowers and fruits of *Senna spectabilis* (Fabaceae). J Braz Chem Soc. 2013;24:230–5.
- Munoz V, Sauvain M, Bourdy G, Callapa J, Rojas I, Vargas L, et al. The search for natural bioactive compounds through a multidisciplinary approach in Bolivia. Part II. Antimalarial activity of some plants used by Mosetene Indians. J Ethnopharmacol. 2000;69(2):139–55.
- Tekwani BL, Walker LA. Targeting the hemozoin synthesis pathway for new antimalarial drug discovery: technologies for *in vitro* beta-hematin formation assay. Comb Chem High Throughput Screen. 2005;8(1):63–79.
- Somsak V, Borkaew P, Klubsil C, Dondee K, Bootprom P, Saiphet B. Antimalarial properties of aqueous crude extracts of *Gynostemma pentaphyllum* and *Moringa oleifera* leaves in combination with artesunate in *Plasmodium berghei*-infected mice. J Trop Med. 2016;20168031392.
- WHO. Guidelines Approved by the Guidelines Review Committee. In: rd, editor. Guidelines for the Treatment of Malaria, vol. 2015. Geneva: World Health Organization. Copyright (c) World Health Organization; 2015.

31. Barradell LB, Fitton A. Artesunate. A review of its pharmacology and therapeutic efficacy in the treatment of malaria. Drugs. 1995;50(4):714–41.
32. Zaman V, Keong LA. Handbook of Medical Parasitology: Churchill Livingstone; 1990.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions



Antiplasmodial activity of Ethanolic extract of Cassia spectabilis DC leaf and its inhibition effect in Heme detoxification

ORIGINALITY REPORT



PRIMARY SOURCES

- | | | |
|---|--|------|
| 1 | s3.amazonaws.com
Internet Source | 1 % |
| 2 | journals.athmsi.org
Internet Source | 1 % |
| 3 | Chinnaperumal Kamaraj, Naveen Kumar Kaushik, Dinesh Mohanakrishnan, Gandhi Elango et al. "Antiplasmodial potential of medicinal plant extracts from Malaiyur and Javadhu hills of South India", Parasitology Research, 2011
Publication | 1 % |
| 4 | Nurcahyo Iman Prakoso, Zahrah Nur Zakiyah, Arida Liyanita, Dwiarso Rubiyanto et al. "Antimalarial Activity of Andrographis Paniculata Ness's N-hexane Extract and Its Major Compounds", Open Chemistry, 2019
Publication | <1 % |
| 5 | Elizabeth Elliott, François Chassagne, Agnès Aubouy, Eric Deharo et al. "Forest Fevers: traditional treatment of malaria in the | <1 % |

southern lowlands of Laos", Journal of Ethnopharmacology, 2020

Publication

-
- 6 Allison Ledoux, Alexis St-Gelais, Ewa Cieckiewicz, Olivia Jansen et al. " Antimalarial Activities of Alkyl Cyclohexenone Derivatives Isolated from the Leaves of ", Journal of Natural Products, 2017 <1 %
- Publication
-
- 7 ousar.lib.okayama-u.ac.jp <1 %
- Internet Source
-
- 8 T. K. Lim. "Edible Medicinal And Non-Medicinal Plants", Springer Science and Business Media LLC, 2014 <1 %
- Publication
-
- 9 S.O. Awe, J.M. Makinde. "Effect of Petroleum Ether Fractions of Morinda lucida on Plasmodium berghei berghei in Mice", Pharmaceutical Biology, 2008 <1 %
- Publication
-
- 10 N Basilico. "A microtitre-based method for measuring the haem polymerization inhibitory activity (HPIA) of antimalarial drugs", Journal of Antimicrobial Chemotherapy, 07/01/1998 <1 %
- Publication
-
- 11 repository.up.ac.za <1 %
- Internet Source

-
- 12 Dikasso, D, E Makonnen, A Debella, D Abebe, K Urga, W Makonnen, D Melaku, A Assefa, and Y Makonnen. "In vivo anti-malarial activity of hydroalcoholic extracts from *Asparagus africanus* Lam. in mice infected with *Plasmodium berghei*", Ethiopian Journal of Health Development, 2007. <1 %
Publication
-
- 13 Guedes, Marjorie Moreira, Ana Carla da Silva Carvalho, Alana Fontales Lima, Silveria Regina de Sousa Lira, Samia Sousa de Queiroz, Edilberto Rocha Silveira, Flávia Almeida Santos, and Vietla Satyanarayana Rao. "Gastroprotective Mechanisms of Centipedic Acid, a Natural Diterpene from *Egletes viscosa* LESS.", Biological & Pharmaceutical Bulletin, 2008. <1 %
Publication
-
- 14 pesquisa.bvsalud.org <1 %
Internet Source
-
- 15 tel.archives-ouvertes.fr <1 %
Internet Source
-
- 16 www.jurnaluldechirurgie.ro <1 %
Internet Source
-
- 17 Ukwe Chinwe V, Ekwunife Obinna I, Epueke Ebele A, Ubaka Chukwuemeka M. "Antimalarial activity of *Ageratum conyzoides*" <1 %

in combination with chloroquine and artesunate", Asian Pacific Journal of Tropical Medicine, 2010

Publication

-
- 18 pubs.acs.org <1 %
Internet Source
-
- 19 www.nepjol.info <1 %
Internet Source
-
- 20 Juyoung Lee, Jae-Sook Ryu. "Current Status of Parasite Infections in Indonesia: A Literature Review", The Korean Journal of Parasitology, 2019 <1 %
Publication
-
- 21 Lalita Wirasathien, Chompunuch Boonarkart, Thitima Pengsuparp, Rutt Suttisri. " Biological Activities of Alkaloids from . ", Pharmaceutical Biology, 2008 <1 %
Publication
-
- 22 Léon Azefack Tapondjou, Anne-Claire Mitaine-Offer, Marc Sautour, Tomofumi Miyamoto, Marie-Aleth Lacaille-Dubois. "Sphingolipids and other constituents from Cordia platythyrsa", Biochemical Systematics and Ecology, 2005 <1 %
Publication
-
- 23 N. T. Huy, K. Mizunuma, K. Kaur, N. T. T. Nhien, M. Jain, D. T. Uyen, S. Harada, R. Jain, <1 %

K. Kamei. "2-tert-Butyl-8-Quinolinamines Exhibit Potent Blood Schizontocidal Antimalarial Activity via Inhibition of Heme Crystallization", *Antimicrobial Agents and Chemotherapy*, 2007

Publication

- | | | |
|----|---|--|
| 24 | cwww.intechopen.com
Internet Source |  <1 % |
| 25 | japtr.org
Internet Source |  <1 % |
| 26 | repositorio-aberto.up.pt
Internet Source |  <1 % |
| 27 | Chandan Singh, Rani Kanchan, Sandeep Chaudhary, Sunil K. Puri. " Linker-Based Hemisuccinate Derivatives of Artemisinin: Synthesis and Antimalarial Assessment against Multidrug-Resistant in Mice ", <i>Journal of Medicinal Chemistry</i> , 2012 |  <1 % |
| 28 | Charris, J.E.. "Synthesis and antimalarial activity of E-2-quinolinyIbenzocycloalcanones", <i>European Journal of Medicinal Chemistry</i> , 200509 |  <1 % |
| 29 | Monti, Diego, Bruno Vodopivec, Nicoletta Basilico, Piero Olliari, and Donatella Taramelli. "A Novel Endogenous Antimalarial: |  <1 % |

Fe(II)-Protoporphyrin IXa (Heme) Inhibits
Hematin Polymerization to β -Hematin
(Malaria Pigment) and Kills Malaria
Parasites[†]", Biochemistry, 1999.

Publication

-
- 30 Muriel Vellutini. "Kallisteine A and B, two new coumarins from the roots of *Peucedanum paniculatum* L, a species endemic to Corsica", Magnetic Resonance in Chemistry, 04/2007 $<1\%$
- Publication
-
- 31 R Baelmans, E Deharo, G Bourdy, V Muñoz, C Quenevo, M Sauvain, H Ginsburg. "A search for natural bioactive compounds in Bolivia through a multidisciplinary approach", Journal of Ethnopharmacology, 2000 $<1\%$
- Publication
-
- 32 Sarah E. Huff, Faiz Ahmad Mohammed, Mu Yang, Prashansa Agrawal et al. "Structure-Guided Synthesis and Mechanistic Studies Reveal Sweetspots on Naphthyl Salicyl Hydrazone Scaffold as Non-Nucleosidic Competitive, Reversible Inhibitors of Human Ribonucleotide Reductase", Journal of Medicinal Chemistry, 2018 $<1\%$
- Publication
-
- 33 Steven J. Burgess, Audrey Selzer, Jane Xu Kelly, Martin J. Smilkstein, Michael K. Riscoe, David H. Peyton. "A Chloroquine-like $<1\%$

Molecule Designed to Reverse Resistance in ",
Journal of Medicinal Chemistry, 2006

Publication

- 34 jmat.mat.or.th <1 %
Internet Source
- 35 patents.justia.com <1 %
Internet Source
- 36 pubs.rsc.org <1 %
Internet Source
- 37 www.finecurepharma.com <1 %
Internet Source
- 38 Dorcas A. Fadare, Oyindamola O. Abiodun,
Edith O. Ajaiyeoba. "In vivo antimalarial
activity of Trichilia megalantha harms extracts
and fractions in animal models", Parasitology
Research, 2013 <1 %
Publication
- 39 Paulo, Alexandra, Marta Figueiras, Marta
Machado et al. "Bis-alkylamine Indolo[3,2-
b]quinolines as Hemozoin Ligands:
Implications for Antimalarial Cytostatic and
Cytocidal Activities", Journal of Medicinal
Chemistry <1 %
Publication
- 40 Sonaly L. Albino, Jamire M. da Silva,
Michelangela S. de C. Nobre, Yvnni M. S. de
M. e Silva et al. "Bioprospecting of <1 %

Nitrogenous Heterocyclic Scaffolds with Potential Action for Neglected Parasitosis: A Review", Current Pharmaceutical Design, 2020

Publication

- 41 Richard K. Cimanga, Gaston L. Tona, Gauthier K. Mesia, Oscar K. Kambu et al. " Bioassay-Guided Isolation of Antimalarial Triterpenoid Acids from the Leaves of . ", Pharmaceutical Biology, 2008 <1 %
- Publication
-
- 42 Wicht, Kathryn J., Jill Michelle Combrinck, Peter J Smith, Roger Hunter, and Timothy J Egan. "Identification and SAR evaluation of hemozoin-inhibiting benzamides active against *Plasmodium falciparum*", Journal of Medicinal Chemistry <1 %
- Publication
-

Exclude quotes Off

Exclude bibliography On

Exclude matches Off